Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



3 Synthetic Biology Stocks That Can Help You Grow in 2014 (and Beyond)

Synthetic biology is relatively new, but the field holds near-limitless potential to shape every aspect of our daily lives. While it's easy to think the industry will only have a major impact in industrial applications, at companies such as Amyris and Solazyme (NASDAQ: SZYM  ) , there are numerous unrelated industries waiting to be forever changed by large-scale genetic tinkering. How can Agilent Technologies (NYSE: A  ) , Intrexon (NYSE: XON  ) , and Solazyme power your portfolio higher in 2014 and beyond?

Agilent Technologies

^SPXTR Chart

^SPXTR data by YCharts.

You may associate Agilent with its core business of providing bioanalytical measurement solutions, but the $20 billion company refuses to miss out on the growth opportunity presented by synthetic biology. After seeing the exploding need for synthetic genes and developing an industry-leading platform for creating short, single-stranded DNA (oligonucleotides), the company made a $21 million investment in DNA synthesis start-up Gen9 that combined each company's sequencing library in return for an equity stake and a position on the board. Prior to that in early 2011, Agilent helped to launch the UC Berkeley Synthetic Biology Institute to spur development in the field.  

I think the investment spree is a brilliant idea. Agilent is positioning itself to greatly increase the number of potential customers that will need its analytical services by fueling growth of the nascent synthetic biology industry. While nothing is guaranteed, the investments could help ease investor concerns of slowing revenue growth and profits that have occurred in the last several fiscal years. I wouldn't begin to think that management is done cutting checks to tap into the market, either.


^SPXTR Chart

^SPXTR data by YCharts.

A few months ago, I voiced three of my concerns with synthetic biology leader Intrexon: The company had partnerships with mostly unproven companies; Wall Street was setting impossible expectations, and shares looked a little frothy given the long time horizon for revenue generation. Since then, collaborations with Johnson & Johnson and Sun Pharma have partially eased my worries about attracting well-funded customers, although Wall Street and a soaring valuation remain red flags. While I'll admit that my views on company valuation are in the process of evolving, I'm still scared of Wall Street's potential to screw things up.

Assuming unrealistic revenue targets don't get in the way, Intrexon is a spectacular long-term growth opportunity that could wield a diverse portfolio of multimillion- or multibillion-dollar products spanning health care, chemical manufacturing, aquaculture, agriculture, and environmental remediation within the next decade. I can't promise shares won't deflate after a 55% climb to begin 2014, but racking up more development collaborations this year and the approval of the first genetically engineered Atlantic salmon would give investors plenty to cheer about.


^SPXTR Chart

^SPXTR data by YCharts.

While I've tried hard to remain objective and level-headed about the tremendous growth opportunity in the making at Solazyme in the last two years, it is difficult to keep my optimism from boiling over as 2014 gets under way. The well-capitalized industrial biotech company will soon begin operations at its first two commercial scale facilities on its way to 120,000 metric tons of annual renewable oil production capacity by mid-2015. In other words, Solazyme will go from a little more than $50 million in annual revenue in 2013 to several hundred million dollars in annual revenue by 2015 and beyond.

Investors aren't out of the woods yet, especially considering the wide range of potential obstacles facing ramp-up, but there likely won't be another opportunity to buy Solazyme under $1 billion after 2014 is in the books. The company is forging ahead with its disruptive platform for creating renewable oils with identical or superior performance compared to those created by other processes and continues to attract partners in various industries. That will help distribute, but not eliminate, development risks while insulating the company's product portfolio from volatility.

Foolish bottom line
The way I see it, there is an obvious growth opportunity brewing in the synthetic biology industry for long-term investors. There will inevitably be hurdles for each company above as they pioneer new technologies with disruptive potential, but the long-term rewards far outweigh the risks of development. If you can stomach the occasional big drop -- and use it as a buying opportunity -- then you, too, can make synthetic biology an integral part of your investment portfolio and retirement plan.

Until synthetic biology arrives in health care...
Intrexon will take some time to disrupt the health-care industry in an impactful way for investors, so you may want to look elsewhere for more immediate opportunities. Let's face it, the best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (2) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 23, 2014, at 6:23 AM, entheogenius wrote:

    Naturally occurring compounds cannot be patented, but an organism genetically modified to produce those same compounds can be.

    I'm in the slow process of building my own Bio-tech company and it is going to be a lot of work. But once I have it I intend to make a whole lot of ethanol with my "magic" yeasts.

    I'll probably put half of Peru,Colombia and Afghanistan out of work in the process. Keep your eyes out for Bio-Systems 9000

  • Report this Comment On January 23, 2014, at 10:36 AM, TMFBlacknGold wrote:


    "Naturally occurring compounds cannot be patented, but an organism genetically modified to produce those same compounds can be."

    Well, a catalyst used to create compounds in a synthetic chemical reaction can be patented. Biological processes use engineered organisms as the catalyst -- a biocatalyst -- so the patent laws do make sense in that regard.


Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2802994, ~/Articles/ArticleHandler.aspx, 8/27/2015 3:50:04 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Maxx Chatsko

Maxx has been a contributor to since 2013. He's currently a graduate student at Carnegie Mellon University merging synthetic biology with materials science & engineering. His primary coverage for TMF includes renewable energy, renewable fuels, and synthetic biology. Follow him on Twitter to keep pace with developments with engineering biology.

Today's Market

updated Moments ago Sponsored by:
DOW 16,550.14 264.63 1.62%
S&P 500 1,968.68 28.17 1.45%
NASD 4,782.38 84.84 1.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/27/2015 3:34 PM
A $36.44 Up +0.82 +2.30%
Agilent Technologi… CAPS Rating: ****
SZYM $2.33 Up +0.10 +4.48%
Solazyme CAPS Rating: ***
XON $44.46 Up +0.17 +0.38%